Place of methotrexate in the treatment of psoriasis in the era of biologic agents

Postepy Dermatologii i Alergologii

Volumn 29, Issue 3, 2012, Pages 182-188

  Dańczak Pazdrowska, Aleksandra ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Biologic therapy; Cyclosporine; Methotrexate; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; ETRETINATE; FOLIC ACID; FOLIC ACID DERIVATIVE; FOLINIC ACID; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANEMIA; BONE MARROW SUPPRESSION; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOXICITY; DRUG WITHDRAWAL; EPILEPSY; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG CANCER; LYMPHOMA; MELANOMA; META ANALYSIS (TOPIC); NAUSEA; NONHUMAN; PARALYSIS; PATHOGENESIS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; VOMITING;

EID: 84864883338     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Zimecki M, Artym J. Działanie metotreksatu na odpowiedź immunologiczna̧ w wybranych modelach doświadczalnych. Postȩpy Hig Med Dosw 2004; 58: 226-35.
2. Świerkot J. Podskórne iniekcje metotreksatu w leczeniu reumatoidalnego zapalenia stawów. Reumatologia 2007; 45: 407-14.
3. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. Arch Dermatol 1958; 78: 200-3.
4. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-37.
5. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriasis arthritis. Ann Rheum Dis 2009; 68: 1387-94.
6. Lindsay K, Fraser AD, Layton A, et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 2009; 48: 569-72.
7. Leon A, Nguyen A, Letsinger J, Koo J. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother 2007; 8: 617-32. (Pubitemid 46547015)
8. Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 2005; 24: 37-45. (Pubitemid 40410097)
9. Potemski P, Płużańska A. MTA (LY 231514) - nowy antagonista kwasu foliowego. Onkol Pol 1999; 2: 163-7.
10. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128: 255-66. (Pubitemid 34534038)
11. Dayan M, Segal R, Mozes E. Cytokine manipulation by methotrexate treatment in murine experimental systemic lupus erythematosus. J Rheumatol 1997; 24: 1075-82. (Pubitemid 27250112)
12. Neurath MF, Hildner K, Becker C, et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA); a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol 1999; 115: 42-55. (Pubitemid 29030362)
13. Seitz M, Zwicker M, Loetscher P. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum 1998; 41: 2032-8. (Pubitemid 28506694)
14. Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systemic review and meta-analysis. Dermatology 2009; 219: 209-18.
15. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-26.
16. Nowak D, Lewandowicz J, Dbkowska B, Marczak J. Combination of methotrexate and prednisone decreases circulating concentrations of interleukin 1 beta and interleukin 6 in patients with rheumatoid arthritis. Poor correlation of cytokine suppression with clinical improvement. Int J Immunopathol Pharmacol 1999; 12: 13-21. (Pubitemid 29178892)
17. Ciesielski CJ, Pflug JJ, Mei J, Piccinini LA. Methotrexate regulates ICAM-1 expression in recipients of rat cardiac allograft. Transpl Immunol 1998; 6: 111-21. (Pubitemid 28454334)
18. Gangemi S, Merendino RA, Guarneni F, et al. Serum levels of interleukin-18 and s-ICAM-1 in patients affected by psoriasis: preliminary considerations. J Eur Acad Dermatol Venereol 2003; 17: 42-6. (Pubitemid 36163653)
19. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66. (Pubitemid 351239154)
20. Heydendael VMR, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-65. (Pubitemid 36975998)
21. Sandhu K, Kaur I, Kumar B, Saraswat A. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from North India. J Dermatol 2003; 30: 458-63. (Pubitemid 36829974)
22. Flytström I, Stenberg B, Svensson Å, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-21. (Pubitemid 350221914)
23. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006; 54: 1013-8.
24. MacKie RM, Fitzsimons MB. Risk of carcinogenicity in patients with psoriasis treated with methotrexate or PUVA singly or in combination. J Am Acad Dermatol 1983; 9: 467-9. (Pubitemid 13051895)
25. Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J Dermatol Treat 2008; 19: 22-6. (Pubitemid 351252717)
26. Pastuszka M, Kaszuba A. Acitretin, a systemic retinoid for the treatment of psoriasis - current state of knowledge. Postep Derm Alergol 2011; 28: 285-92.
27. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis; double-blind randomized controlled trial. Lancet 2004; 363: 675-81. (Pubitemid 38296553)
28. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63. (Pubitemid 28459913)
29. Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in patient newly unresponsive to infliximab. Arch Dermatol 2004; 140: 366. (Pubitemid 38332496)
30. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711-6.
31. Yang CP, Kuo MC, Guh JY, Chen HC. Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of literature. Renal Failure 2006; 28: 95-7.
32. Stankiewicz-Habrat P, Brzeźińska-Wcisło L. Changes in the dynamics of hair growth in rats after application of methotrexate, metoprolol and naproxen. Postep Derm Alergol 2010; 27: 11-7.
33. van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modyfying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8: R151.
34. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular disease in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-7.
35. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis; a prospective study. Lancet 2002; 359: 1173-7. (Pubitemid 34304256)
36. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131-5.
37. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006; 154: 1169-74. (Pubitemid 43727401)
38. Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. Br J Dermatol 2007; 157: 213. (Pubitemid 46934285)
39. Lloyd ME, Carr M, McElhatton P, et al. The effect of methotrexate on pregnancy, fertility and lactation. QJM 1999; 92: 551-63. (Pubitemid 29501961)
40. French AE, Koren G. Effect of methotrexate on male fertility. Can Family Phys 2003; 49: 577-8.
41. El-Beheiry A, El-Mansy E, Kamel N, Salama N. Methotrexate and fertility in men. Arch Androl 1979; 3: 177-9. (Pubitemid 10213439)
42. Hirsh A. Male subfertility. BMJ 2003; 327: 669-72.
43. Metex package leaflet.
44. Iven H, Brash H. Cephalosporins increase the renal clearance of methotrexate and 7-hydroxymathotrexate in rabbits. Cancer Chemother Pharmacol 1990; 26: 139-43. (Pubitemid 20153806)
45. Weinstein G, Frost P. Mathotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971; 103: 33-8.
46. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailibility: oral solution, ora tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-9. (Pubitemid 24031585)
47. Kabisch S, Weigand T, Plischke H, Menninger H. Bioavailability of methotrexate (MTX) following different routes of application. Akt Rheumatol 2004; 29: 197-200. (Pubitemid 39215492)
48. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose mathotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-8. (Pubitemid 38451248)
49. Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical afficacy and safety of subcutaneous versus oral administration of methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 73-81.
50. Alsufyani K, Ortiz-Alvarez O, Carbal DA, et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopatic arthritis who failed oral methotrexate. J Rheumatol 2004; 31: 179-82. (Pubitemid 38067542)
51. Bingham SJ, Buch MH, Lindsay S, et al. Parenteral methotrexate should be given before biological therapy. Rheumatology 2003; 42: 1009-10. (Pubitemid 37220978)
52. Papp K, Gulliver W, Lynde C, et al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg 2011; 15: 210-9.
53. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137-74.
54. Mease PJ. Psoriatic arthritis - update on pathophysiology, assessment, and management. Bull NYU Hosp Jt Dis 2010; 68: 191-8.
55. thAugust 2011.